Triglycerides

Management of lipids and residual cardiovascular risk has been a growing concern in endocrinology, and new data in this area are encouraging.

Management of lipids and residual CV risk has been a primary focus in cardiology for decades, and new data in this area are encouraging. Much emphasis has been placed on the use of therapies including PCSK9 inhibitors, statins and ezetimibe to achieve target LDL levels. But controlling LDL does not always control CVD risk, and because some patients are not able to achieve LDL and other targets on existing therapies, new options are needed.

The consumption of sugar-sweetened beverages contributes to adverse changes in HDL and triglyceride concentrations, which also increases the risk for dyslipidemia, according to a study published in the Journal of the American Heart Association.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-APOCIII-LRx for the treatment of patients with hypertriglyceridemia at risk for or with established CVD met its primary endpoint of significant triglyceride lowering.

Low HDL cholesterol levels can be used to monitor long-term, average high triglyceride levels and remnant cholesterol in much the same way a high HbA1c is an indicator of long-term, average high glucose levels, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Plaque progression in patients assigned icosapent ethyl (Vascepa, Amarin) vs. placebo.

PHILADELPHIA — Icosapent ethyl for patients at high CV risk conferred cost-savings in-trial and during patients’ lifetime, according to findings presented at the American Heart Association Scientific Sessions.

PHILADELPHIA — Interim data using coronary CT angiography demonstrated benefits of icosapent ethyl as an adjunct to statin therapy on several plaque characteristics at 9 months in adults with high triglycerides and coronary atherosclerosis.

PHILADELPHIA — Two novel RNA interference agents, one targeting apolipoprotein C-III and one targeting angiopoietin-like protein 3, improved various lipid parameters in early studies with healthy volunteers, according to new data presented at the American Heart Association Scientific Sessions.